We are absolutely thrilled to hear the official announcement from NHS England confirming the Vertex (USA) drug Trikafta will now be funded for 90% of Cystic Fibrosis patients in England. There will be a delay for Scotland and Wales and Northern Ireland who have to agree to accept the same agreement. See the NHS press release here.
NHS patients with cystic fibrosis will be among the first in Europe to benefit from the new triple therapy for the condition following a landmark deal, NHS Chief Executive Simon Stevens has announced today. pic.twitter.com/c0RBdTGHwe
— NHS England (@NHSEngland) June 30, 2020
This will be life changing for most patients, although not a cure, improving lung function and overall health. It will have amazing results for most , taking some patients from 25% lung function to 50% and more. The new treatment should be available in 60-90 days.
'Luis, and so many others, will get the future they deserve.' — Christina Walker (@guatemalagirl), whose son has #CysticFibrosis, shares her gratitude following today's landmark deal for new life-transforming treatment for people with cystic fibrosis. https://t.co/zRp0SWY7sp pic.twitter.com/NedR2WiR9k
— NHS England (@NHSEngland) June 30, 2020
#KaftrioNow just amazing news @MattHancock thank you for keeping to your word and seeing this through. This day has changed everything. The future is so very very bright for our daughter and so many with #cysticfibrosis. Thank you pic.twitter.com/JTVfnNvnwg
— Cllr Liz Brennan (@Elizabe46045399) June 30, 2020
So, today an amazing drug called Kaftrio has been licenced for people with CF with at least one copy of a particular gene mutation (Df508) on the NHS. This means my 8 year old daughter has a chance to live a normal healthy life beyond 40. *happy cry* #Kaftrio #cysticfibrosis pic.twitter.com/0uECWsDdZS
— sarah 🪲 (@ms_soundbird) June 30, 2020